Callos Andrew 4

What Happened
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics (CYTK), sold 3,639 shares in an open-market/private sale on March 31, 2026. The shares were sold at $65.00 per share for a total proceeds of $236,535. This was a sale (S), which is often routine insider selling and not necessarily a signal about company prospects.

Key Details

• Transaction date: 2026-03-31
• Transaction type/code: Open-market or private sale (S)
• Shares sold: 3,639 at $65.00 per share
• Total value: $236,535
• Shares owned after transaction: Not specified in the information provided
• Filing date/accession: Form filed 2026-03-31 (no late filing indicated)
• Footnotes/notable plan: No 10b5-1 plan, tax-withholding, or other special footnotes referenced in the provided details

Context
Insider sales are common for diversification or liquidity and do not by themselves indicate management’s view of the company’s future. Purchases are generally more directly bullish; since this filing reports a sale and no exercise or award, there’s no immediate indication of new equity grants or cashless option exercises from the information supplied.